Why Geron Corporation Doubled since August 2018

02:48 09/14/2018

Since bottoming out at $3.25 in August 2017, shares of Geron Corporation GERN  have more than doubled to nearly $7 a share. All as it waits on good news from Johnson & Johnson JNJ . The biotech's lead pipeline candidate, imetelstat, is also its only pipeline candidate. And it's very possible that Geron could soon receive some very good news for it. At the moment, Johnson & Johnson is collaborating with Geron on evaluating the drug in a phase II clinical study targeting treatment of myelofibrosis (MF) and in a phase 2/3 clinical study for treating myelodysplastic syndromes (MDS). And by the end of this month, Johnson & Johnson will decide if it will continue developing the drug. The good news is that all signs are pointing to a positive outcome with Johnson & Johnson, as they continue to feature imetelstat in pipeline updates as one of four new oncology drugs that it expects to submit for regulatory approval by 2021. Should Johnson & Johnson continue, it could be big news for the GERN stock. GERN would receive a $65 million milestone payment. In addition, the chances of Geron having its first product on the market within the next few years would increase.

This article has been provided by a Chasing Markets contributor. All content submitted by this author represent their personal opinions, and should be considered as such for entertainment purpose only. All opinions expressed are those of the writer, and may not necessarily represent fact, opinions, or bias of Chasing Markets.
Most Read